Good morning, everyone, and how are you today? We are doing just fine, thank you, as we quickly adjust time zones and prepare for a public speaking exercise at what amounts to Woodstock for pharmacists. Nonetheless, this has not stopped us from the usual routine of foraging for interesting items, although our usual posting will take a hit today and tomorrow, since we have a few meetings before the trek back to the Pharmalot campus. Meanwhile, here are the aforementioned tidbits. Hope your day is smashing and please do keep in touch.
A string of multibillion-dollar pharmaceutical deals announced this week brings us to a record-setting year in which drug makers and biotechs have spent $342 billion snapping up smaller companies to bolster their pipelines, MarketWatch tells us. While the number of U.S. pharmaceutical and biotechnology deals has increased year over year, from 365 in 2018 to 484 so far this year, it’s the size of 2019’s mergers and acquisitions that is notable. This year’s $342 billion in M&A activity far surpasses any other year since 1995.